Similar to our system, in metastatic melanoma cells characterized by BRAF mutations, resistance to MEK and BRAF inhibitors is mediated by MAPK rebound, and more specifically, Erk re-activation is mediated by Pak134. Here, BRAF is linked to melanoma.